Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus regorafenib and PD-1 inhibitor for colorectal cancer liver metastases after second-line failure
ChiCTR2200062903Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Sep 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib, fluorouracil, oxaliplatin and folinic acid in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective Response Rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
regorafenibfluorouraciloxaliplatinfolinic acid
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2200062903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062903.